Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects
NCT ID: NCT00931060
Last Updated: 2009-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2007-11-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of BCAA Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in CLD Patients
NCT04246918
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
NCT06121492
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
NCT04858412
Effect of Amino Acid on Muscle Damage
NCT03319147
BCAA Supplemental Study
NCT03339232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We intend to study the effect of oral administered BCAA on the metabolism of ammonia and amino acids across the leg-muscles by means of catheters inserted into the femoral artery (A) and vein (V). Muscle blood flow (F; L/min) will be determined by constant infusion of indocyanine green and indicator dilution principle. Arterial blood flow and A and V concentrations of ammonia and amino acids will be measured before an oral load of BCAA (0.45 g BCAA/kg body weight) and after 1 and 3 hours. The metabolism of ammonia will also be estimated by means of 13N-NH3 PET scans.
Hypothesis: BCAA increases the uptake of ammonia in muscle tissue and lowers arterial ammonia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Branched chain amino acids
Patients with cirrhosis. Healthy subjects age and sex matched
Branched chain amino acids
Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Branched chain amino acids
Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 6 healthy subjects age and sex matched
Exclusion Criteria
* Pregnancy/breast-feeding
35 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PET Centre. Aarhus University Hospital.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Keiding, MD
Role: STUDY_CHAIR
PET Centre and Medical department V, Aarhus Sygehus, Aarhus University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15580
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.